Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $236.22 --0%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
SQZB, RENO, LUNA, More
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
SQZB, RENO, LUNA, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.07), $0.11 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- Morgan Stanley starts Rio Tinto ADR coverage at underweight, sees 14% downside
- Barclays Upgrades Safestore Holdings Plc. (SAFE:LN) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
